(Q35680646)

9 August 2017

1 reference

title

New strategies in the treatment and prevention of allergic diseases (English)

1 reference

9 August 2017

2

Stephen T Holgate

1 reference

9 August 2017

1

Hans Michael Haitchi

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Expert Opinion on Investigational Drugs

9 August 2017

published in

1 reference

9 August 2017

volume

13

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

107-124

1 reference

Exposure to cockroach allergen in the home is associated with incident doctor-diagnosed asthma and recurrent wheezing.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Environmental exposure to endotoxin and its relation to asthma in school-age children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Allergy and allergic diseases. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Allergy, parasites, and the hygiene hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

The germless theory of allergic disease: revisiting the hygiene hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Asthma: an epidemic of dysregulated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

A comparison of salmeterol and formoterol in attenuating airway responses to short-acting β2-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

New millennium bronchodilators for asthma: single-isomer beta agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Effect of ciclesonide on allergen challenge in subjects with bronchial asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Soft drug design: general principles and recent applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Cytokine modulators as novel therapies for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Requirement for IL-13 independently of IL-4 in experimental asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Cytokine-directed therapies for the treatment of chronic airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Tumour necrosis factor alpha: a potential mediator of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Effect of oromucosal administration of IFN-alpha on allergic sensitization and the hypersensitive inflammatory response in animals sensitized to ragweed pollen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Chemokines in allergic lung inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Chemokines and their role in airway hyper-reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Structure, function, and inhibition of chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Update on the therapeutic potential of PDE4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Suplatast tosilate inhibits thymus- and activation-regulated chemokine production by antigen-specific human Th2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Effects of suplatast tosilate on airway inflammation and airway hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Inhibition of p38 MAP kinase as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Transcription factors and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Treatment of asthma with drugs modifying the leukotriene pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Leukotriene receptor antagonists as add-on therapy for adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

A randomized controlled trial of intravenous montelukast in acute asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Zafirlukast has no beneficial effects in the treatment of chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Leukotrienes as mediators of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Antihistamines in late-phase clinical development for allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Kinin receptors in pain and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Nitric oxide in asthma. Pathogenic, therapeutic, or diagnostic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Reactive nitrogen and oxygen species in airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Role of nitric oxide in allergic inflammation and bronchial hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Reactive oxygen species as mediators in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Dietary antioxidants and asthma in adults: population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Prospective study of diet and decline in lung function in a general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Dietary antioxidants and ozone-induced bronchial hyperresponsiveness in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Antioxidant supplementation and lung functions among children with asthma exposed to high levels of air pollutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Effect of apocynin on ozone-induced airway hyperresponsiveness to methacholine in asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Dietary micronutrients/antioxidants and their relationship with bronchial asthma severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Long-term clinical efficacy of grass-pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

CpG motifs in bacterial DNA and their immune effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Medicinal chemistry and therapeutic potential of CpG DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Synthetic IgE peptide vaccine for immunotherapy of allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

A new class of cyclosporin analogues for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Oral tacrolimus for severe recalcitrant atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

The inverse association between tuberculin responses and atopic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Anti-allergy properties of fermented foods: an important immunoregulatory mechanism of lactic acid bacteria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Probiotics in the management of atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Susceptibility genes in asthma and allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Pharmacogenetics, pharmacogenomics and airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

RASONs: a novel antisense oligonucleotide therapeutic approach for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Small RNA: can RNA interference be exploited for therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Treatment of experimental asthma by long-term gene therapy directed against IL-4 and IL-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

21 January 2018

Gene therapy for asthma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

The role of surfactant in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Dietary antioxidant vitamin intake and lung function in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

DNA antisense therapy for asthma in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.2.107

10.1517/13543784.13.2.107

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference